Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women
Authors:
- Us Preventive Services Task ForceUFUs Preventive Services Task Force
- David C. GrossmanDGDavid C. Grossman
- Karina W. DavidsonKDKarina W. Davidson
- John W. EplingJEJohn W. Epling
Open Access
- 12 December 2017
- journal article
- practice guideline
- Published by American Medical Association (AMA) in JAMA
- Vol. 318 (22) , 2224-2233
Abstract
The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.Keywords
This publication has 11 references indexed in Scilit:
- Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized TrialsObstetrical & Gynecological Survey, 2018
- The 2017 hormone therapy position statement of The North American Menopause SocietyMenopause, 2017
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2015
- Long‐term safety of unopposed estrogen used by women surviving myocardial infarction: 14‐year follow‐up of the ESPRIT randomised controlled trialBJOG: An International Journal of Obstetrics & Gynaecology, 2014
- Changing Concepts: Menopausal Hormone Therapy and Breast CancerJNCI: Journal of the National Cancer Institute, 2012
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of MenopauseEndocrine Practice, 2011
- The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal WomenObstetrics & Gynecology, 2005
- Effects of Estrogen With and Without Progestin on Urinary IncontinenceJAMA, 2005
- Effect of Estrogen Therapy on Gallbladder DiseaseJAMA, 2005
- Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic ProceduresThe Women's Health Initiative Randomized TrialJAMA, 2003